Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy
ConclusionThese findings suggest that patients with multiple sclerosis receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza‐specific vaccine responses.
Source: European Journal of Neurology - Category: Neurology Authors: H. K. Olberg, G. E. Eide, R. J. Cox, Å. Jul‐Larsen, S. L. Lartey, C. A. Vedeler, K.‐M. Myhr Tags: Original Article Source Type: research
More News: Brain | Copaxone | Gilenya | H1N1 | Influenza | Influenza Vaccine | Multiple Sclerosis | Neurology | Study | Swine Flu (H1N1) Vaccine | Tysabri | Vaccines